trends in BIOTECHNOLOGY

Author Index

Subject Index

Index of Books Reviewed

2000

Volume 18
Issues 1–12
ISSN 0167 7799

ELSEVIER
SCIENCE
LONDON

Trends in Biotechnology

Elsevier Science London,
84 Theobald's Road,
London, UK WC1X 8RR
Tel: +44 020 7611 4400
Fax: +44 020 7611 4401
e-mail: ttec@current-trends.com

Advisory Editorial Board

M. Aizawa *Tokyo, Japan*
A. Atkinson *Warwick, UK*
J. Bailey *Zurich, Switzerland*
G. Carrea *Milan, Italy*
W.T. Coakley *Cardiff, UK*
R.L. Coffman *CA, USA*
A. Colman *Edinburgh, UK*
D. Cowan *London, UK*
J. Durant *London, UK*
M. Hoare *London, UK*
J. Holbrook *Bristol, UK*
D. Jones *Dunedin, New Zealand*
D. Kell *Aberystwyth, UK*
E. Krebbers *DE, USA*
L. Macaskie *Birmingham, UK*
B. Mattiasson *Lund, Sweden*
J.D. Murray *Davis, USA*
E. Palmer *Basel, Switzerland*
C. Sander *MA, USA*
M. Uhlén *Stockholm, Sweden*
K. Van't Riet *Wageningen, The Netherlands*
U. Von Stockar *Lausanne, Switzerland*
H.H. Weetall *MD, USA*
J. Wells *San Francisco, USA*

Editor Meran Owen

Assistant Editors Annabel Hinde and Suzanne Berry

Editorial Administrator Liam Benison, Sheema Sheikh and Natalie Baderman

Publishing Manager Robert Brines

© 2001 Elsevier Science Ltd.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science London, 84 Theobald's Road, London, UK WC1X 8RR.

Author Index

Abbreviations: BR = Book Review L = Letter MR = Meeting Report

A

Addona, T.A., *see* Williams, C.
Aittaleb, M., *see* Gerday, C.
Akeson, M., *see* Deamer, D.W.
Aldey, C., *see* Morris, S.
Alexandre, G. and Zhulin, I.B., Laccases are widespread in bacteria 41 *(L)*
Allen, E.E. and Hood, L., Biotechnology, inquiry, and public education 329
Anderson, R.T., *see* Coates, J.D.
Archard, F., *see* Barillot, E.
Ashman, K., 'Fishing with chips' 328
Attwood, T.K., Bridging the gap with ORF ESTs 363
Auberson, L., Transgenic crops from another perspective 404 *(MR)*
Ayazi-Shamlou, P., *see* Levy, M.S.

B

Bachinger, T. and Mandenius, C-F., Searching for process information in the aroma of cell cultures 494
Ballesteros, A., *see* Gill, I.
Barillot, E. and Archard, F., XML: a lingua franca for science? 331
Bentahir, M., *see* Gerday, C.
Binz, P-A., Proteome and Protein Analysis 362 *(BR)*
Blanvillain, R., *see* Varoquaux, F.
Bogorad, L., Engineering chloroplasts: an alternative site for foreign genes, proteins, reactions and products 257
Borch, K. and Rasmussen, B., An analytical approach to the implementation of genetically modified crops 484
Borgia, J.A. and Fields, G.B., Chemical synthesis of protein 243
Boulnois, G.J., Drug discovery in the new millennium: the pivotal role of biotechnology 31
Bouriotis, V., *see* Tsigos, I.
Bowen, B., *see* Somers, D.A. *(MR)*
Boyce-Jacino, M.T., *see* Pfost, D.R.
Bradbury, A., Coupling phenotype to genotype: selecting phages, ribosomes and artificial cells 3 *(MR)*
Bradbury, A., Evolution of display technologies 183 *(MR)*
Bradbury, A., Molecular library technologies at the millennium 131 *(MR)*
Bramucci, M.G. and Nagarajan, V., Industrial wastewater bioreactors: sources of novel microorganisms for biotechnology 501
Brandén, L., Peptide Nucleic Acids: Protocols and Applications 361 *(BR)*
Brecker, L. and Ribbons, D.W., Biotransformations monitored *in situ* by proton nuclear magnetic resonance spectroscopy 197
Brown, W.R.A., Mee, P.J. and Shen, M.H., Artificial chromosomes: ideal vectors? 218
Brown, W.R.A., Response from Brown 403 *(L)*
Buitelaar, R.M., *see* Ooijkaas, L.P.
Bulfield, G., Farm animal biotechnology 10

C

Cabral, J.M.S., *see* Ferreia, G.N.M.
Cantor, C.R., Biotechnology in the 21st century 6
Carrea, G. and Colombo, G., Coupling high enzyme activity and stability: a challenging target 401 *(L)*
Cascante, M., Ortega, F. and Marti, E., New insights into our understanding of the regulation and organization of cell factories 181 *(L)*
Cate, J., Crystallization of Nucleic Acids and Proteins: A Practical Approach (2nd edn) 275 *(BR)*
Chessa, J-P., *see* Gerday, C.
Chisti, Y., Animal-cell damage in sparged bioreactors 420
Claverie, P., *see* Gerday, C.
Clemons, P.A., Be still my beating heart 407
Coates, J.D. and Anderson, R.T., Emerging techniques for anaerobic bioremediation of contaminated environments 408
Colins, T., *see* Gerday, C.
Colman, A. and Kind, A., Therapeutic cloning: concepts and practicalities 192
Colombo, G., *see* Carrea, G.
Cowan, D.A., Microbial genomes – the untapped resource 14
Craig, I.W., McClay, J., Plomin, R. and Freeman, B., Chasing behaviour genes into the next millennium 22
Crespi, R.S., Genomics, proteomics and patents 405 *(MR)*
Cullum, B.M. and Vo-Dinh, T., The development of optical nanosensors for biological measurements 388
Cysewski, G.R., *see* Lorenz, R.T.

D

D'Amico, S., *see* Gerday, C.
Dan, N., Synthesis of hierarchical materials 364
de Grey, A.D.N.J., Mitochondrial gene therapy: an arena for the biomedical use of inteins 394
de Jong, G., *see* Perez, C.
de Miguel, Y.R., What next in combinatorial chemistry 43 *(MR)*
Deamer, D.W. and Akeson, M., Nanopores and nucleic acids: prospects for ultrarapid sequencing 147
Delseny, M., *see* Varoquaux, F.
Demain, A.L., Microbial biotechnology 26
Dhingra, N., *see* Lal, R.
Dorman, G. and Prestwich, G.D., Using photolabile ligands in drug discovery and development 64
Drayer, J., *see* Perez, C.
Drioli, E., *see* Giorno, L.
Dumont, J., *see* Gerday, C.
Dunnill, P., *see* Levy, M.S.

E

Eder, P.S., *see* Xavier, K.A.

F

Feller, G., *see* Gerday, C.
Ferreira, G.N.M., Monteiro, G.A., Prazeres, D.M.F. and Cabral, J.M.S., Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications 380
Fetcher, M., *see* Griengl, H.
Fetrow, J.S., *see* Skolnick, J.
Fields, G.B., *see* Borgia, J.A.
Figeys, D., Large-scale screening on small scale 363
Figeys, D., The Achilles' heel of proteomics 483
Flynn, T., *see* Ghiradi, M.L.
Freeman, B., *see* Craig, I.W.

G

Gallois, P., *see* Varoquaux, F.
Gander, B., *see* Johansen, P.
Garden, R.W., *see* Li, L.
Garsoux, G., *see* Gerday, C.
Georlette, D., *see* Gerday, C.
Gerday, C., Aittaleb, M., Bentahir, M., Chessa, J-P., Claverie, P., Collins, T., D'Amico, S., Dumont, J., Garsoux, G., Georlette, D., Hoyoux, A., Lonhienne, T., Meuwis, M-A. and Feller, G., Cold-adapted enzymes: from fundamentals to biotechnology 103
Ghiradi, M.L., Zhang, L., Lee, J.W., Flynn, T., Seibert, M., Greenbaum, E. and Melis, A., Microalgae: a green source of renewable H_2 506

Gilbert, D.R., Schroeder, M. and van Helden, J., Interactive visualization and exploration of the relationships between biological objects 487
Gill, I. and Ballesteros, A., Bioencapsulation within synthetic polymers (Part 1): sol–gel encapsulated biologicals 282
Gill, I. and Ballesteros, A., Bioencapsulation within synthetic polymers (Part 2): non-sol–gel protein–polymer biocomposites 469
Giordano, T., *see* Xavier, K.A.
Giorno, L. and Drioli, E., Biocatalytic membrane reactors: applications and perspectives 339
Glassey, J., Montague, G. and Mohan, P., Issues in the development of an industrial bioprocess advisory system 136
Glassman, A.B., *In Situ* Hybridization: A Practical Approach 40 *(BR)*
Godzic, A., Crystallography made Crystal Clear: A Guide for Users of Macromolecular Models 361 *(BR)*
Goldberg, R.B., *see* Somers, D.A. *(MR)*
Goldfarb, P.S., *see* Wiseman, A.
Gourley, M.F., *see* Gourley, P.L.
Gourley, P.L. and Gourley, M.F., Biocavity lasers for medicine 443
Grant, D.M., *see* Pfost, D.R.
Greenbaum, E., *see* Ghiradi, M.L.
Griengl, H., Schwab, H. and Fetcher, M., The synthesis of chiral cyanohydrins by oxynitrilases 252
Griffin, T.J. and Smith, L.M., Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry 77
Grötzinger, J., *see* Kallen, K-J.

H
Hadlaczky, G., *see* Perez, C.
Haslberger, A., *see* Jank, B.
Heath, C.A., Cells for tissue engineering 17
Heijnen, S.J., *see* Nicolella, C.
Hesse, F. and Wagner, R., Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures 173
Hinde, A., Evolution, not revolution 230
Hinmann, M.B., Jones, J.A. and Lewis, R.V., Synthetic spider silk: a modular fiber 374
Hood, L., *see* Allen, E.E.
Housby, J.N. and Sohail, M., When is a chip not a chip? 439 *(MR)*
Hudson, P.J., Antibody Fusion Proteins 128 *(BR)*
Humphreys, R.E., *see* Xu, M.
Hunter, A.C., *see* Moghimi, S.M.
Hyoux, A., *see* Gerday, C.

J
Jain, K.K., Biotechnological applications of lab-chips and microarrays 278 *(MR)*
Jank, B. and Haslberger, A., Recombinant DNA insertion into plant retroviruses 326 *(L)*
Jenkins, N., Carbohydrate Biotechnology Protocols 180 *(BR)*
Jermutus, L. and Osbourn, J.K., How do you find new drugs using polypeptide display? 280 *(MR)*
Jiang, Z., *see* Xu, M.
Johansen, P., Gander, B., Merkle, H.P. and Sesardic, D., Ambiguities in the preclinical quality of microparticulate vaccines 203
Jones, J.A., *see* Hinmann, M.B.
Jungar, C., *see* Ohlson, S.
Juza, M., Mazzotti, M. and Morbidelli, M., Simulated moving-bed chromatography and its application to chirotechnology 108

K
Kafetzopoulos, D., *see* Tsigos, I.
Kallen, K-J., Grötzinger, J. and Rose-John, S., New perspectives in the design of cytokines and growth factors 455
Kaur, H., *see* Lal, R.
Kazlauskas, R.J., Applied Biocatalysis 437 *(BR)*
Kell, D.B. and King, R.D., On the optimization of classes for the assignment of unidentified reading frames in functional genomics programmes: the need for machine learning 93
Kell, D.B., Screen idols: faster, smaller, cheaper and smarter 186 *(MR)*
Khanna, R., *see* Lal, R.
Killard, A.J. and Smyth, M.R., Creatine biosensors: principles and designs 433
Kind, A., *see* Colman, A.
Kinderlerer, J., Is a European convention on the ethical use of modern biotechnology needed? 87 *(MR)*
King, R.D., *see* Kell, D.B.
Klibanov, A.M., Answering the question: 'Why did biocatalysis in organic media not take off in the 1930s?' 85 *(L)*
Kumari, R., *see* Lal, R.
Kuwabara, T., Warashina, M. and Taira, K., Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity 462
Kvittingen, L., Response from Kvittingen 86 *(L)*

L
Lal, R., Kumari, R., Kaur, H., Khanna, R., Dhingra, N. and Tuteja, D., Regulation and manipulation of the gene clusters encoding type-I PKSs 264
Lee, J.W., *see* Ghiradi, M.L.
Levy, M.S., O'Kennedy, R.D., Ayazi-Shamlou, P. and Dunnill, P., Biochemical engineering approaches to the challenges of producing pure plasmid DNA 296
Lewis, R.V., *see* Hinmann, M.B.
Li, L., Garden, R.W. and Sweedler, J.V., Single-cell MALDI: a new tool for direct peptide profiling 151
Lim, H.A. and Venkatesh, T.V., Bioinformatics in the pre- and post-genomic eras 133 *(MR)*
Liu, L. and Groß, M., A glimpse at changes to come? 440 *(MR)*
Lonhienne, T., *see* Gerday, C.
Lorenz, R.T. and Cysewski, G.R., Commercial potential for *Haematococcus* microalgae as a natural source of astaxanthin 160

M
Ma, J.K-C., Recombinant Antibodies: Applications in Plant Science and Plant Pathology 225 *(BR)*
Mandenius, C-F., *see* Bachinger, T.; Ohlson, S.
Mark, M.C., *see* Nicolella, C.
Marti, E., *see* Cascante, M. *(L)*
Martinou, A., *see* Tsigos, I.
May, O., Reinventing the wheel 42 *(L)*
Mayo, K.H., Recent advances in the design and construction of synthetic peptides: for the love of basics or just for the technology of it 212
Mazur, B., *see* Somers, D.A. *(MR)*
Mazzotti, M., *see* Juza, M.
McCarthy, J.J., Genetic studies: look no further than your own backyard 441
McClay, J., *see* Craig, I.W.
McLane, K., Recombinant Antibodies 320 *(BR)*
Mee, P.J., *see* Brown, W.R.A.
Melis, A., *see* Ghiradi, M.L.
Merkle, H.P., *see* Johansen, P.
Messina, D.N., Bioinformatics: Methods and Protocols 224 *(BR)*
Meuwis, M-A., *see* Gerday, C.
Miller, H.I., Biotechnology food standards hunger for scientific rationale 232
Miller, J.A., Jr and Nagarajan, J., The impact of biotechnology on the chemical industry in the 21st century 190
Moghimi, S.M. and Hunter, A.C., Poloxamers and poloxamines in nanoparticle engineering and experimental medicine 412
Mohan, P., *see* Glassey, J.
Montague, G. *see* Glassey, J.
Monteiro, G.A., *see* Ferreira, G.N.M.
Morbidelli, M., *see* Juza, M.
Morris, S. and Aldey, C., Evolving European GM regulation: an example of biopolitics at work 325 *(L)*
Mountain, A., Gene therapy: the first decade 119

N

Nagarajan, J., *see* Miller, J.A., Jr

Nagarajan, V., *see* Bramucci, M.G.

Nicolella, C., Mark, C.M., van Loosdrecht, M.C.M. and Heijnen, S.J., Particle-based biofilm reactor technology 312

O

Oda, L.M. and Soares, B.E.C., Genetically modified foods: economic and public acceptance in Brazil 188

Odorico, J.S., *see* Thompson, J.

Ohlson, S., Jungar, C., Strandh, M. and Mandenius, C-F., Continuous weak-affinity immunosensing 49

O'Kennedy, R.D., *see* Levy, M.S.

Ooijkaas, L.P., Weber, F.J., Buitelaar, R.M., Tramper, J. and Rinzema, A., Defined media and inert supports: their potential as solid state fermentation production systems 356

Ortega, F., *see* Cascante, M. *(L)*

Osbourn, A.E., Biochemistry of Plant Secondary Metabolism and Functions of Plant Secondary Metabolites and their Exploitation in Biotechnology 321 *(BR)*

P

Perez, C., de Jong, G., Drayer, J. and Hadlaczky, G., Satellite DNA-based artificial chromosomes – chromosomal vectors 402 *(L)*

Pfost, D.R., Boyce-Jacino, M.T. and Grant, D.M., A SNPshot: pharmacogenetics and the future of drug therapy 334

Plomin, R., *see* Craig, I.W.

Polkinghorne, J.C., Ethical issues in biotechnology 8

Prazeres, D.M.F., *see* Ferreira, G.N.M.

Prestwich, G.D., *see* Dorman, G.

Q

Qui, G., *see* Xu, M.

R

Rangel-Aldao, R., Biotechnology in the Developing World and Countries in Economic Transition 322 *(BR)*

Rasmussen, B., *see* Borch, K.

Reichert, J.M., New biopharmaceuticals in the USA: trends in development and marketing approvals 1995–1999 364

Ribbons, D.W., *see* Brecker, L.

Ridgway, T., *see* Wiseman, A.

Rinzema, A., *see* Ooijkaas, L.P.

Rose-John, S., *see* Kallen, K-J.

S

Sackmann, E. and Tanaka, M., Supported membranes on soft polymer cushions: fabrication, characterization and applications 58

The Safety in Biotechnology Working Party of the European Federation of Biotechnology, safe biotechnology 10: DNA content of biotechnological process waste 141

Schroeder, M., *see* Gilbert, D.R.

Schuster, S., Biotechnology *in silico*: metabolic proteomics of *Haemophilus influenzae* 328

Schuster, S., Breeding of *Escherichia coli* based on colour 442

Schwab, H., *see* Griengl, H.

Seibert, M., *see* Ghiradi, M.L.

Sesardic, D., *see* Johansen, P.

Sheehan, P.E., Heading towards the light 481 *(MR)*

Shen, M.H., *see* Brown, W.R.A.

Skolnick, J. and Fetrow, J.S., From genes to protein structure and function; novel applications of computational approaches in the genomic era 34

Smith, L.M., *see* Griffin, T.J.

Smith, T., Genetics Databases 223 *(BR)*

Smyth, M.R., *see* Killard, A.J.

Snoep, J., Gearing up for a quantitative understanding of cell (dys)function 1 *(MR)*

Soares, B.E.C., *see* Oda, L.M.

Sohail, M., *see* Housby, J.N.

Somers, D.A., Mazur, B., Goldberg, R.B. and Bowen, B., The impact of molecular biology on crop production and crop protection 185 *(MR)*

Srinivasan, C.S. and Thirtle, C., Agriculture and Intellectual Property Rights: Economic, Institutional and Implementation Issues in Biotechnology 480 *(BR)*

Stacey, G., Recombinant animal cells: risk assessment and containment 277 *(MR)*

Stockwell, B.R., Frontiers in chemical genetics 449

Strandh, M., *see* Ohlson, S.

Strivens, M., Not who you know, but what you know 227 *(MR)*

Sweedler, J.V., *see* Li, L.

Szilvassy, S.J., Boning up on tissue engineering 482

T

Taira, K., *see* Kuwabara, T.

Tanaka, M., *see* Sackmann, E.

Thompson, J. and Odorico, J.S., Human embryonic stem cell and embryonic germ cell lines 53

Tramper, J., *see* Ooijkaas, L.P.

Tsigos, I., Martinou, A., Kafetzopoulos, D. and Bouriotis, V., Chitin deacetylases: new versatile tools in biotechnology 305

Tuteja, D., *see* Lal, R.

V

van Helden, J., *see* Gilbert, D.R.

van Loosdrecht, M.C.M., *see* Nicolella, C.

VanCott, T.C., Vaccine Adjuvants: Preparation Methods and Protocols 511 *(BR)*

Varoquaux, F., Blanvillain, R., Delseny, M. and Gallois, P., Less is better: new approaches for seedless fruit production 233

Venkatesh, T.V., *see* Lim, H.A. *(MR)*

Vo-Dinh, T., *see* Cullum, B.M.

von Hofe, E., *see* Xu, M.

W

Wackett, L.P., Environmental biotechnology 19

Wagner, R., *see* Hesse, F.

Warashina, M., *see* Kuwabara, T.

Ward, K.A., Transgene-mediated modifications to animal biochemistry 99

Weber, F.J., *see* Ooijkaas, L.P.

Wilkins, M., Proteomic paradigms for perceiving purpose 91 *(MR)*

Williams, C. and Addona, T.A., The integration of SPR biosensors with mass spectrometry: possible applications for proteome analysis 45

Wiseman, A., Goldfarb, P.S., Ridgway, T. and Wiseman, H., Biomarkers, bioindicators or ecotranslators to biomonitor oestrogen mimics? 1 *(L)*

Wiseman, H., *see* Wiseman, A.

X

Xavier, K.A., Eder, P.S. and Giordano, T., RNA as a drug target: methods for biophysical characterization and screening 349

Xu, M., Qui, G., Jiang, Z., von Hofe, E. and Humphreys, R.E., Genetic modification of tumor antigen presentation 167

Z

Zhang, L., *see* Ghiradi, M.L.

Zhulin, I.B., *see* Alexandre, G.

Subject Index

Abbreviations: BR = Book Review MR = Meeting Report L= Letter

A

Additives, cell protection 426–431

Adenovirus, gene transfer systems 121–122

Advisory systems, industrial, developmental issues 136–141

Ageing, mitochondrial DNA 394

Agricultural biotechnology 19–21, 87–90 *(MR)*, 185–186 *(MR)*, 188–190

  genetically modified crops 484–486

  intellectual property rights 480 *(BR)*

  microorganisms 30–31

  see also Genetic modification

Airlift reactors 312–319

Allosteric maxizymes 462–468

Allotopic expression 395–396

Alternative energy 20

Amino acid production 26–27

Amperometric biosensors 433–437

  see also Biosensors

Anaerobic bioremediation, hydrocarbon contamination 408–409

Analysis, multivariate 139–140

Anchoring proteins, soft polymer films 61

Animal biotechnology *see* Transgenic animals

Animal cells, recombinant 277–278 *(MR)*

Animal welfare, European Union (EU) 88 *(MR)*

Antibiotic resistance, biosafety 143–145

Antibodies

  antibody–antigen interactions 49–52

  display 4 *(MR)*

  FDA approval of monoclonal antibodies 364–369

  fusion proteins 128–129 *(BR)*

  genes 131–133 *(MR)*

  recombinant *see* Recombinant antibodies

Antioxidants 164–165

  astaxanthin 160–167

Antitumor therapy

  maxizymes 463–464

  vaccines 167–172

Aquaculture, microalgae 165–166

  see also Microalgae

Aroma emissions, metabolic activity 494–500

Artificial chromosomes 218–223

  satellite DNA-based 402–403 *(L)*

Artificial intelligence, bioprocess advisory system 136–141

Artificial organs 346–347

Artificial ribozymes, allosteric 464–467

Association studies, gene identification 22

Astaxanthin, *Haematococcus* microalgae production 160–167

Automation

  combinatorial chemistry 44 *(MR)*

  drug discovery 33

  proteomics 92 *(MR)*

B

Bacteria *see* Microorganisms: *specific bacterial genera*

Bacterial laccases 41–42 *(L)*

Behavioural genes 22–26

Benzophenone, drug discovery and development 64–77

Bilayers, colloidal 370–374

Biocatalysis 197–202, 252–256

  applications 437 *(BR)*

  cold-adapted enzymes 106–107

  environmental biotechnology 20–21

  enzyme stability 401–402 *(L)*

  membrane reactors 339–349

  in organic media 85–86 *(L)*, 86 *(L)*

  sol–gel encapsulated biologicals 282–296

Biocavity lasers 443–448

Biochemical engineering, plasmid DNA production 296–305

Biocomposites 469–477

Bioconversions, microbial biotechnology 28

Biodiversity 14–15

Bioencapsulation

  non-sol–gel protein–polymer 469–479

  sol–gel encapsulation 282–296

Biofilms 312–320

Bioimmobilization 282–296

  protein–polymer biocomposites 469–479

Bioindicators 1 *(L)*

Bioindustry, expert systems 136

Bioinformatics 7, 133–135 *(MR)*, 223–224 *(BR)*, 224–225 *(BR)*

  applications 278–280 *(MR)*

  cancer research 134 *(MR)*

  data integration and access 227–228 *(MR)*

  data mining 228–230 *(MR)*

  drug discovery 33

  pharmacogenomics 230–231 *(MR)*

  proteomics 91–92 *(MR)*

  World Wide Web 331–333

Biological nanosensors 391–392

Biomarkers 1 *(L)*

Biomedicine

  biocavity lasers 443–448

  non-ionic surfactants 412–420

Biomimetic synthesis 371

Biomonitors, oestrogen mimics *see* Biosensors

Biopharmaceuticals

  biosafety 173–180, 277–278 *(MR)*

  cell culture 173–180

  good manufacturing practice (GMP) 177–178

  risk assessment 177–178

  trends in development and marketing (USA) 364–369

  see also Drugs; Pharmaceuticals

Biophysical characterization, RNA–protein complexes 349–356

Biopolitics 325–326 *(L)*

Bioprocesses 190–191

  advisory system, developmental issues 136–141

  electronic noses 494–500

Bioreactors *see* Reactor technology

Bioremediation

  anaerobes 408–412

  cold-adapted enzymes 106

  environmental biotechnology 20

Biosafety 141–146, 188–190

  antibiotic resistance 143–145

  DNA in waste 142–145

  genetically modified organisms (GMO) 142–145

  recombinant animal cells 277–278 *(MR)*

  risk assessment 142

  transgenic crops 404–405 *(MR)*

  waste management 142

  see also Risk assessment

Biosensors 45–48

  amperometric 433–437

  biomonitors of oestrogen mimics 1 *(L)*

  creatinine 433–437

  enzyme immobilization 434–435

  immunosensing 49–52

  nanosensors 388–393

    see also Nanosensors

  potentiometric 433–437

  sensor configuration 435–436

  sol–gel encapsulation 282–296

  supported membranes 61–63

  surface plasmon resonance (SPR) 45–48, 49–52, 353

Bioseparations, simulated moving-bed chromatography 116–117

Biotechnology

  agricultural *see* Agricultural biotechnology

  developing world 322–323 *(BR)*

  education 329–330

  European Union (EU) directives 87–90 *(MR)*

  future 6–7

  public opinion 9–10, 90 *(MR)*, 329–330

  - safety *see* Biosafety
- Biotransformation 252–256
  - enzymic 197–202
- Biphasic reactors *see* Reactor technology
- Blastocyst, pre-implantation mammalian development 54
- Bone regeneration, tissue engineering 482
- Bubble-associated damage, sparging 420–432

C

- Caged compounds 72–75
- Cancer
  - bioinformatics 134 *(MR)*
  - detection, growth rates 446–447
  - metabolic control analysis (MCA) 2 *(MR)*
  - vaccines 167–172
  - *see also* Tumors
- Carbohydrate biotechnology protocols 180 *(BR)*
- Cardiac failure, ryanodine receptors 407
- Carotenoids, metabolic engineering 442
- cDNA display technologies 4 *(MR)*
  - *see also* Display technologies
- Cell banks 174–175
- Cell culture, mammalian
  - cultivation techniques 175–176
  - embryonic germ cells 53–57
  - embryonic stem cells 53–57, 192–196
  - human therapeutics, manufacture 173–180
  - tissue engineering 17–19
- Cell cultures, electronic noses 494–500
- Cell cycle analysis, lasers 446
- Cell damage, sparging 420–432
- Cell differentiation 192–196
- Cell factories, regulation and organization 181–182 *(L)*
- Cell protection, bioreactor additives 426–431
- Cell therapy 192–196
- Characterization
  - microbial populations 501–505
  - soft polymer films 60–61
- Chemical diversity, chemical genetics 450–452
- Chemical genetics 449–455
  - phenotype-based screens 452–453
  - target identification 453–454
- Chemical industry, biotechnology 190–191
- Chemical nanosensors 390–391
  - *see also* Nanosensors
- Chemical synthesis
  - peptides 212–217
  - protein 243–251
- Chemistry, green *see* Environmental biotechnology
- Chemochromic screening, H_2-producing microalgae 509
- Chimeric genes, maxizyme targeting 467
- Chiral drugs *see* Drugs
- Chirotechnology, simulated moving-bed chromatography 108–118
- Chitin deacetylase 305–312
- Chitosan, applications 308–310
- *Chlamydomonas reinhardtii* 506–511
- Chloroplasts, engineering 257–263
- Chromatography
  - plasmid DNA purification 382–387
  - simulated moving-bed (SMB) 108–118
- Chromosomes
  - artificial *see* Artificial chromosomes
  - Philadelphia chromosome, ribozyme design 462–463
- Clinical trials, gene therapy 120–121
- Cloning
  - ethics 8–10
  - multiplex 15–16
  - therapeutic 192–196
- Clustering and dendrograms, visualization methods 489–491
- Codex 232–233
- Cold-adapted enzymes 103–107
  - *see also* Enzymes
- Collagen 243–251
- Colloidal bilayers 370–374
- Colloidal templating 371
- Combinatorial chemistry 43–44 *(MR)*
- Combinatorial libraries 272
- Computational genomics 34–39
- Computational techniques, biology 224–225 *(BR)*
- Condensation strategies, synthetic silk 376–377
- Containment, GMOs 277–278 *(MR)*
- Country profiles, biotechnology 322–323 *(BR)*
- Creatinine biosensors 433–437
- Crop production, molecular biology 185–186 *(MR)*
  - genetically modified crops 484–486
  - transgenic guidelines 404–405 *(MR)*
- Crop protection, molecular biology 185–186 *(MR)*
- Crystallography 361–362 *(BR)*
  - DNA 275 *(BR)*
  - multiwavelength anomalous dispersion (MAD) phasing 275 *(BR)*
  - RNA 275 *(BR)*
- Cyanohydrins, chiral 252–256
- Cysteine biosynthesis, transgenic sheep 99–100
- Cytokines, design 455–461

D

- Databases 228–230 *(MR)*
  - genetic 223–224 *(BR)*
  - websites 41–42 *(L)*
- Data exchange, World Wide Web 331–333
- Data integration 227–228 *(MR)*
- Data visualization, complex biological data 487–494
- Deacetylation, chitin 305–312
- Defined media, solid state fermentation 356–360
- Design
  - biosensors on supported membranes 61–63
  - cytokines and growth factors 455–461
  - peptides 212–217
  - vaccines 203–211
- Detergents, cold-adapted enzymes 106
- Deuterium
  - effects 197–202
  - exchange 197–202
- Developing world, biotechnology 322–323 *(BR)*
- Development and marketing (USA), biopharmaceuticals 364–369
- Diagnostics, lasers 443–444
- Directed biosynthesis, microbial biotechnology 29
- Directed evolution 7, 42–43 *(L)*
- Display technologies 3–5 *(MR),* 183–184 *(MR)*
  - alternative systems 5 *(MR)*
  - cDNA 4 *(MR),* 183 *(MR)*
  - peptide display 5 *(MR)*
  - phage display 3–5 *(MR),* 131–132 *(MR),* 280–281 *(MR)*
  - ribosome display 131–132 *(MR),* 280–281 *(MR)*
  - scFv 4 *(MR),* 183–184 *(MR)*
    - *in vitro* / *in vivo* 183–184 *(MR)*
  - yeast display 131–132 *(MR)*
- Diversity
  - microbial 14–15
  - molecular 131 *(MR)*
- DNA
  - content of biotechnological waste 141–146
  - crystallography 275 *(BR)*
  - gene transfer systems 123–124, 326–327 *(L)*
  - MALDI-TOF analysis 77–84
  - microarrays *see* Microarrays
  - mitochondrial 394–399
  - plasmid downstream processing 380–388
  - plasmid production, large scale 296–305
  - PNA analogues 361 *(BR)*
  - sequencing 147–151
  - vaccines 380–388
- DNA chips 278–279 *(MR)*
  - *see also* Microarrays, DNA
- DNA shuffling, cytokines 459–460
- Downstream processing, plasmid DNA 380–388
- Drugs
  - chiral
    - biocatalysis 85–86 *(L)*
    - racemic resolution 116
  - discovery and development
    - biotechnology role 31–33
    - chemical technology 336
    - expression analysis 32–33
    - phage display 280–281 *(MR)*
    - pharmacogenetics 334–338
    - photolabile ligands 64–77

    ribosome display 280–281 *(MR)*
    trends in marketing and development (USA) 364–369
    see also Biopharmaceuticals; Pharmaceuticals
  targeting, RNA 349–356

E

Economics, genetically modified foods 188–190
Ecotranslators 1 *(L)*
Education, biotechnology 329–330
Electrode design, biosensors 434
Electronic noses, applications 494–500
Electrophoresis, 2D-PAGE 91 *(MR),* 483
Electroporation, gene transfer systems 124–125
Embryonic germ cells 53–57
Embryonic stem cells 53–57, 192–196
  transplantation 55–56, 195
Enantiomers
  biocatalysis, enantioselectivity 85–86 *(L)*
  enantiopure intermediates 252–256
  separation 110–118
Enantioselectivity 339–349
Environmental biotechnology 19–21
  anaerobic bioremediation 408–409
  microalgae: a green source of renewable H_2 506–511
Environmental issues
  biomonitors 1 *(L)*
  biotechnology 9, 87–88 *(MR)*
Enzyme immobilization, biosensors 434–435
Enzymes
  bacterial laccases 41–42 *(L)*
  biocatalysis 85–86 *(L)*
    stability 401–402 *(L)*
  cold-adapted 103–107
  engineering 42–43 *(L)*
  microbial production 30
  structure and adaptation 104–106
  thermostability 401–402 *(L)*
Epitopes
  epitope shuffling 457–459
  protein–protein interactions 455–456
Epoxy resin–protein biocomposites 469–471
Erythromycin 266
Escherichia coli
  metabolic engineering 442
  see also Microorganisms
Ethics
  biotechnology 8–10, 87–90 *(MR)*
  pharmacogenomics 231 *(MR)*
European Union (EU) directives
  biotechnology 87–90 *(MR)*
  directive 90/220/EEC 325–326 *(L)*
Evolution
  directed 7, 42–43 *(L)*
  microbial metabolic pathways 501–505
  in vitro 131–133 *(MR)*
Experimental medicine, nanoparticle engineering 412–420
Expert systems 136–141
Expressed sequence tags, human genome project 363
Expression analysis, drug discovery 32–33

F

Fabrication, soft polymer films 58–60
Fault detection 136–141
FDA
  biopharmaceuticals 364–369
  food regulation 232–233
  orphan drugs, approval 366–367
Fermentation, solid-state 356–360
Fibers, synthetic spider silk 374–379
Fluidization, biofilms 316–318
Fluorescent techniques 481–482 *(MR)*
Folding, peptides 212–217
Food and Drug Administration *see* FDA
Food biotechnology 88 *(MR),* 232–233
Food industry 232–233
  cold-adapted enzymes 106
  European Union (EU) 88 *(MR),* 325–326 *(L)*
  FDA regulation 232–233
  standards 232–233
  transgenic foods 8–10, 188–190
    see also Genetic modification
  see also Agricultural biotechnology
Fossil fuels, environmental biotechnology 19–20
F pilus, phage display 3 *(MR)*
Fruit, seedless 233–242
Functional assignment, drug discovery 33
Functional classes, genes 93–98
Fungal biotechnology 27–28
FUN genes 93–98
Fusion proteins
  antibody 128–129 *(BR)*
  cytokines 459
Fuzzy functional forms, computational biology 35–38

G

Gels, slow-release, polymers 415
Gene clusters, polyketide synthases (PKSs), modular 264–274
Gene construction, synthetic silk protein 375–376
Gene containment 257–263
Gene expression
  allotopic 395–396
  analysis 134 *(MR)*
  artificial chromosomes 218–223
  In situ hybridization: a practical approach 40 *(BR)*
  spider silk proteins 377–378
  visualization of data 488–494
Gene functional classes 93–98
  class assignment 93–94
  FUN genes 93–98
  statistical pattern recognition 95–97
  taxonomy 96
  websites 94
Gene identification 22–26, 134 *(MR)*
  association studies 22
  see also Gene mapping; Genomics
Gene mapping
  linkage analysis 22
    linkage disequilibrium (LD) 441
  MALDI-TOF analysis 77–84
Gene therapy 119–128, 218–223, 230–231 *(MR)*
  clinical trials 120–121
  inteins 394–399
  mitochondrial DNA 394–399
  plasmid DNA downstream processing 380–388
  plasmid DNA production 296–305
  prospects 125–126
  vectors *see* Gene transfer systems
Genetic modification
  European Union (EU)
    directives 87–90 *(MR)*
    regulation 325–326 *(L)*
  foods 88 *(MR),* 232–233, 325–326 *(L)*
    economics 188–190
    ethics 8–9
    see also Agricultural biotechnology; Food industry
  organisms (GMO) 88–89 *(MR),* 99–102, 185–186 *(MR),* 484–486
    biosafety 142–145
    ethics 8–10
    farm animal biotechnology 10–13
    risk assessment 277–278 *(MR),* 484–486
    see also Transgenic animals
  public opinion 9–10, 13, 90 *(MR),* 188–190
Genetic modulation of tumor antigen presentation 167–172
Genetics
  behavioural 22–26
  chemical 449–455
  drug discovery and development 32–33
  linkage disequilibrium (LD) 441
  multifactorial disorders 22
Gene transfer systems 119–125
  adenovirus 121–122
  condensed DNA particles 124
  downstream processing, plasmid DNA 380–388
  electroporation 124–125
  lipids 124
  naked DNA 123–124
  needle free injection 124
  plant retrotransposons 326–327 *(L)*
  retrovirus 122–123
  satellite DNA based vectors 402–403 *(L)*
  see also Gene therapy
Genomics 185–186 *(MR),* 223–224 *(BR)*
  animal biotechnology 10–12
  computational approaches 34–39
  drug discovery and development 32–33
  functional 34–38, 93–98

  human genome project 363
  microarrays, DNA 328–329
  microbial genomes 14–16
  patents 405–406 *(MR)*
  sequencing 133–134 *(MR)*
  structural 34–38, 134–135 *(MR)*
  see also Pharmacogenomics
Genotype–phenotype coupling 3–5 *(MR)*
Glyoxylate cycle 101–102
GMOs *see* Genetic modification
Good manufacturing practice (GMP), biopharmaceuticals 177–178
Green algae *see* Microalgae
Green chemistry *see* Environmental biotechnology
Growth factors, design 455–461
Guidelines, transgenic crops 404–405 *(MR)*

H
Haematococcus microalgae
  commercial potential as a source of astaxanthin 160–167
  see also Microalgae
Haemophilus influenzae, proteomics 328
Hammerhead ribozyme 462–468
Health, human
  European Union (EU) 88 *(MR)*
  health care 230–231 *(MR)*
Heart failure 407
Heavy-metal contamination, anaerobic bioremediation 411
Hemoglobin, intracellular measurement 445–446
α-Hemolysin 148
Hierarchical materials, synthesis 370–374
HTML 331–333
Human Genome Project
  expressed sequence tags 363
  see also Genomics
Human therapeutics
  manufacture 167–172
  pharmaceuticals 173–180
Hydrocarbon contamination, anaerobic bioremediation 408–409
Hydrogen production, microalgae 506–511
Hydroxynitrile lyases 252–256

I
Imaging, medical, nanoparticles 413–414
Immobilized enzyme, biocatalysis 339–349
Immunocytochemistry, MALDI 157–158
Immunogenicity, vaccines 203–211
Immunology, plant science 225 *(BR)*
Immunosensing 49–52
Immunotherapy 167–172
  genetic modulation of tumor antigen presentation 167–172
Individualized medicine, SNPs 334–338
Industrial bioprocess advisory system 136–141
Industry, European Union (EU) 89 *(MR)*
Inert supports, solid state fermentation 356–360
Inquiry in education 329–330
In situ hybridization: a practical approach 40 *(BR)*
In situ monitoring 197–202
Inteins, mitochondrial gene therapy 394–399
Intellectual property rights (IPR), agricultural biotechnology 480 *(BR)*
Interactive visualization, biological objects 488–494
Internet *see* Websites
Intracellular libraries 132–133 *(MR)*
IPR (intellectual property rights), agricultural biotechnology 480 *(BR)*

K
Knowledge-based systems 136–141

L
Laboratory chips (lab-chips)
  applications 278–280 *(MR)*
  see also Microarrays, DNA
Laccases 41–42 *(L)*
Lasers in biomedicine 443–448
Libraries
  combinatorial 272
  intracellular 132–133 *(MR)*
  molecular library technologies 131–133 *(MR)*
  peptide 280–281 *(MR)*
  see also Display technologies
Ligands, photolabile 64–77
Linkage disequilibrium (LD), genetic studies 441
Linkers, combinatorial chemistry 43–44 *(MR)*
Lipases, biocatalysis 85–86 *(L)*
Lipids, gene transfer systems 124
Lysine biosynthesis 100–101

M
Machine learning, functional genomics 93–98
Major-histocompatibility complex class II, antigen presentation 168–171
MALDI
  immunocytochemistry 157–158
  MALDI-TOF, polymorphism analysis 77–84
  peptide profiling 151–160
  see also Mass spectrometry
Mammalian development, pre-implantation 53–57
Manufacturing
  recombinant animal cells 277–278 *(MR)*
  see also Bioprocesses
Mapping objects onto a Euclidean space 491–493
Marketing and development (USA), biopharmaceuticals 364–369
Marks, Cara, obituary 131
Mass spectrometry
  biosensor integration 45–48
  MALDI *see* MALDI
  MALDI-TOF, polymorphism analysis 77–84
  protein identification 46, 362 *(BR)*
  proteomics 91–92 *(MR)*
  RNA–protein complexes 353
  screening, high-throughput 363–364
Matrix-assisted laser desorption/ionization *see* MALDI
Maxizymes 462–468
Medicines *see* Drugs
Membrane reactors, biocatalysis 339–349
Mesophases, finite 371–372
Metabolic activity, aroma emissions 494–500
Metabolic control
  analysis (MCA) 1–3 *(MR),* 181–182
  complexity 2 *(MR)*
  regulation 2 *(MR)*
Metabolic engineering 1–3 *(MR)*
  carotenoids 442
Metabolites
  plant secondary 321–322 *(BR)*
  primary, microbial production 26–27
  secondary, microbial production 28–29
MHC class II, tumor antigen presentation 168–171
Microalgae
  aquaculture 165–166
  a green source of renewable H_2 506–511
Microarrays, DNA 439–440 *(MR)*
  applications 278–280 *(MR)*
  data mining 228–230 *(MR)*
  genomics 328–329
  see also Bioinformatics
Microelectromechanical systems (MEMS) 440–441 *(MR)*
Microengineering, MEMS 440–441 *(MR)*
Microfluidics 279
Microorganisms
  bacterial laccases 41–42 *(L)*
  bioremediation 20, 106
  biotechnology 26–31
  industrial wastewater bioreactors 501–505
  microbial genomes 14–16
  psychrophiles 103
  recombinant 29–31
Microparticles, microspheres 203–211
Microscopy, near-field optical 388–390
Miniaturization 44 *(MR)*
Mitochondrial DNA, gene therapy 394–399
Modular fibers, synthetic spider silk 374–379
Molecular diversity 3–5 *(MR),* 131 *(MR),* 183–184
Molecular library technologies *see* Libraries
Molecular modelling, cytokine engineering 455–457
Molecular selection 131–133 *(MR)*
Monitoring, *in situ* 197–202
Monoclonal antibodies, FDA approval 364–369

Multi-copper oxidases 41–42 *(L)*
Multidrug resistance, inhibition 416
Multifactorial genetic disorders 22
Multiplex cloning 15–16
Multivariate analysis 139–140
Mutations, mitochondrial DNA 394–399

N
Nanofiber fabrication 388–389
Nanoparticle engineering 412–420
Nanopores 147–151
Nanosensors
  biological 391–392
  chemical 390–391
  optical 388–393
Nanotechnology 440–441 *(MR)*
Near-field optical microscopy 388–390
Needle free injection, gene transfer 124
Nitroaromatic contamination, anaerobic bioremediation 410–411
NodB proteins 308
Nodulation proteins, rhizobial 308
Non-ionic surfactants, biomedicine 412–420
Non-sol–gel protein–polymer, bioencapsulation 469–479
Nuclear magnetic resonance (NMR) spectroscopy
  proteins 362 *(BR)*
  proton-NMR 197–202
Nuclear transfer 192–196
Nuclear transformation 257–263

O
Objects, biological, interactive visualization 488–494
Oestrogen mimics, biomonitors 1 *(L)*
Oligomers, chitin 305
Oligonucleotide arrays, RNA–protein complexes 353–354
Optical nanosensors 388–393
Organic solvents, biocatalysis 85–86 *(L)*
Orphan drugs, FDA approval 366–367
Oxynitrilases 252–256

P
PAGE *see* Electrophoresis
Parasitology, metabolic control analysis (MCA) 3 *(MR)*
Parthenocarpy, fruit 233–242
Patents
  fruit 237–241
  genomics 405–406 *(MR)*
  pharmacogenomics 231 *(MR)*
  proteomics 405–406 *(MR)*
Peptide-amphiphile 243–251
Peptide display 5 *(MR)*
Peptide nucleic acids, protocols and applications 361 *(BR)*
Peptides
  chemical synthesis 212–217
  mass finger-printing 45–48
  profiling 151–160
  structure 212–217
Perchlorate contamination, anaerobic bioremediation 409–410
Pesticides, environmental biotechnology 20
Phage display *see* Display technologies
Pharmaceuticals
  human therapeutics 173–180
  see also Biopharmaceuticals; Drugs
Pharmacogenomics 6–7, 230–231 *(MR)*, 334–338, 439 *(MR)*
  see also Genomics
Phenotype-based screens, chemical genetics 452–453
Phenotype–genotype coupling 3–5 *(MR)*
Philadelphia chromosome, ribozyme design 462–463
Photoaffinity labelling (PAL) 64–77
Photolabile ligands 64–77
Photolithography 64–77
Photosynthesis, H_2 production in green algae 506–511
Plant science 225 *(BR)*
  biotechnology 21, 225 *(BR)*
  retrotransposons 326–327 *(L)*
  secondary metabolites, applications 321–322 *(BR)*
  transgenic crops 404–405 *(MR)*
Plant secondary metabolites 321–322 *(BR)*
Plasmid DNA
  downstream processing 380–388
  manufacture 380
  production, gene therapy 296–305
  purification 382–387
PNA 361 *(BR)*
Poloxamers 412–420
Poloxamines 412–420
Polygenic traits 257–263
Polyketide synthases (PKSs), modular 264–274
Polymers
  biocomposites 469–477
  bioencapsulation 282–296, 469–479
  combinatorial chemistry supports 43 *(MR)*
  gels 415
  soft polymer films 58–64
Polymorphism, single-nucleotide (SNP)
  association studies 22–26
  high-throughput screening 23
  individualized medicine 334–338
  MALDI-TOF analysis 77–84
  pharmacogenetics 334–338
  scoring 439 *(MR)*
Polyurethane–protein biocomposites 473–474
Polyvinyl–protein biocomposites 471–473
Post-transcriptional markers, phenotype-based assays 453
Post-translational modification, peptide profiling 156
Potentiometric biosensors 433–437
  see also Biosensors
Preventative medicine 230–231 *(MR)*
Productivity, performance index 181–182
Protein
  analysis
    laser measurements 446
    methodologies 362 *(BR)*
    single-cell 151–160
  anchoring, soft polymer films 61
  arrays 439–440 *(MR)*
  chemical synthesis 243–251
  crystallization 275 *(BR)*
  folding 243–251
  function prediction 34–37
  identification by mass spectrometry 46, 362 *(BR)*
  protein–polymer biocomposites 469–479
  recombinant, FDA approval 364–369
  silk 374–375
  structure 243–251, 362 *(BR)*
    prediction 36–37
  topology comparisons 487–494
Protein–protein interactions, epitopes 455–456
Proteomics
  2D-electrophoresis 91 *(MR)*, 483
  automation 92 *(MR)*
  biosensors and mass spectrometry 45–48
  drug discovery and development 32–33
  Haemophilus influenzae 328
  MALDI 92 *(MR)*, 151–160
  methodologies 362 *(BR)*
  paradigms 91–92 *(MR)*
  patents 405–406 *(MR)*
Psychrophilic enzymes 103–107
Public education, biotechnology 329–330
Public opinion
  animal biotechnology 13
  biotechnology 9–10, 90 *(MR)*, 329–330
  European Union (EU) 89 *(MR)*
  genetically modified foods 188–190, 484–486
Purification, plasmid DNA, large scale 296–305

Q
Quality control, vaccines 203–211

R
Racemic resolution, chiral drugs 116
Rapamycin 266–267
Reactor technology
  biocatalytic membranes 339–349
  biphasic reactors 339–349
  cell damage in sparged bioreactors 420–432
  industrial waste water reactors, novel microorganisms 501–505
  particle-based biofilms 312–320
Receptor–ligand interactions 455–461
Recombinant animal cells 277–278 *(MR)*
Recombinant antibodies 183–184, 320–321 *(BR)*
  plant science 225 *(BR)*

Recombinant DNA 232–233, 277–278 *(MR)*
  microbial biotechnology 27
  plant retrotransposons 326–327 *(L)*
Recombinant microorganisms 29–31
Recombinant proteins, FDA approval 364–369
Recombination, homologous 257–263
Regulations, GMOs 277–278 *(MR)*, 325–326 *(L)*
Research and development (R&D), drug discovery 32
Retrotransposons, recombinant DNA 326–327 *(L)*
Retroviral gene transfer systems 122–123
Ribosome display 131–132 *(MR)*, 280–281 *(MR)*
Ribozymes 462–468
  design, Philadelphia chromosome cleavage 462–463
Rifamycin 267–269
Risk assessment
  biopharmaceuticals 177–178
  biotechnological waste 142
  GMOs 277–278 *(MR)*
  plant retrotransposons 326–327 *(L)*
RNA
  crystallography 275 *(BR)*
  drug targeting 349–356
RNA–protein complexes, biophysical characterization 349–356
Ryanodine receptors, cardiac failure 407

S
Safety *see* Biosafety
Satellite DNA-based artificial chromosomes (SATACs) 402–403 *(L)*
ScFv display technologies 4 *(MR)*
Screening
  chemochromic screening, H_2-producing microalgae 509
  high-throughput 23, 186–187 *(MR)*, 363–364
  phenotype-based screens 452–453
  polymorphism, single-nucleotide 23
  RNA–protein complexes 349–356
Selection
  Darwinian 183–184
  molecular 131–133 *(MR)*
Sensor configuration, biosensors 435–436
Sequencing
  DNA 147–151
  genomic 133–134 *(MR)*
  nucleic acid 147–151
  peptide profiling 157–158
  sequence analysis 224–225 *(BR)*
  sequence annotation 134–135 *(MR)*
  ultrarapid 147–151
Silicone–protein biocomposites 474–477
Single-nucleotide polymorphism (SNP) *see* Polymorphism, single-nucleotide
Soft polymer films 58–64
Sol–gel encapsulation 282–296
Solid-phase synthesis 43–44 *(MR)*
Solid-state fermentation, fungi 356–360
Solution-structural information 197–202
Sparging, cell damage 420–432
Spider silk, synthetic 374–379
Statistical pattern recognition, gene functional classes 95–97
Stem cells
  embryonic 53–57, 192–196
  tissue engineering 17–18
Stenospermocarpy 234
Structural genomics *see* Genomics
Structured information, data exchange languages 331–333
Supported membranes 58–64
  biosensor design 61–63
Surface plasmon resonance (SPR) 45–48
  continuous weak-affinity immunosensing 49–52
  RNA–protein complexes 353
Surfactants, hierarchical synthesis 370–373
Synthesis
  chemical *see* Chemical synthesis
  hierarchical materials 370–374
  peptide nucleic acids 361 *(BR)*
Synthetic polymers
  bioencapsulation 282–296, 469–479
  see also Polymers

T
Targeting
  chimeric genes 467
  nanoparticles 413–415
  target discovery 32, 64–77
  target identification 453–454
Taxonomy
  gene functional classes 96
  microbial 96
Technology foresight (TF), genetically modified crops 484–486
Templating, colloidal 371
Terminator technology 241
  see also Genetic modification
Textile industry 106
T-helper cells, antigen presentation modulation 167–171
Thermodynamics, biospheres 131 *(MR)*
Thermostability, enzymes 401–402 *(L)*
Threonine biosynthesis 100–101
Tissue engineering
  bone regeneration 482
  cultured cells 17–19
  supported membranes 58–64
Topology comparisons, proteins 487–494
Transcription-based markers, phenotype-based assays 452–453
Transgenic animals
  animal welfare 88 *(MR)*
  farm animal biotechnology 12–13
  modifications to biochemistry 99–102
  see also Genetic modification
Transgenic crops 404–405 *(MR)*
  see also Agricultural biotechnology; Food industry
Transgenic foods *see* Food industry
Transplantation, embryonic stem cells 195
Trends in development and marketing (USA), biopharmaceuticals 364–369
Tumors
  antigen presentation, genetic modulation 167–172
  treatment, maxizymes 463–464
  vaccines 167–172
  see also Cancer
Tylosin fermentation 136–141

V
Vaccines
  antigenicity 203–211
  antitumor therapy 167–172
  DNA 296–305, 380–388
  microparticulate, design 203–211
  Vaccine Adjuvants: Methods and Research Protocols 511 *(BR)*
Vectors
  artificial chromosomes 218–223, 402–403 *(L)*
  see also Gene transfer systems
Visualization methods, complex biological data 487–494
Vitamin production 27

W
Waste management
  biocatalytic membrane reactors 347
  biofilm reactors 312–320
  see also Biosafety
Wastewater bioreactors
  sources of novel microorganisms 501–505
  see also Reactor technology
Websites
  databases 41–42 *(L)*
  gene functional classes 94
  patents 405–406 *(MR)*
World Wide Web, bioinformatics 331–333
WWW *see* World Wide Web

X
XML (extensible markup language) 331–333

Y
Yeast display 131–132 *(MR)*
  see also Display technologies

Index of Books Reviewed

B

Bishop, M.J., ed., *Genetics Databases* 223

Breitling, F. and Dübel, S., eds, *Recombinant Antibodies* 320

Bucke, C., ed., *Carbohydrate Biotechnology Protocols* 180

C

Chamow, S.M. and Ashkenazi, A., eds, *Antibody Fusion Proteins* 128

D

Ducruix, A. and Giegé, R., eds, *Crystallization of Nucleic Acids and Proteins: A Practical Approach (2nd edn)* 275

H

Harper, K. and Ziegler, A., eds, *Recombinant Antibodies: Applications in Plant Science and Plant Pathology* 225

K

Kamp, R.M., Kyriakidis, D. and Choli-Papadopoulou, T., eds, *Proteome and Protein Analysis* 362

M

Misener, S. and Krawetz, S.A., eds, *Bioinformatics: Methods and Protocols* 224

N

Nielsen, P.E. and Egholm, M., eds, *Peptide Nucleic Acids: Protocols and Applications* 361

O

O'Hagan, D., ed., *Vaccine Adjuvants: Preparation Methods and Research Protocols* 511

R

Rhodes, G., *Crystallography Made Crystal Clear: A Guide for Users of Macromolecular Models* 361

S

Santaniello, V., Evenson, R.E., Zilberman, D. and Carlson, G.A., eds, *Agriculture and Intellectual Property Rights. Economic, Institutional and Implementation Issues in Biotechnology* 480

Straathof, A.J.J. and Adlercreutz, P., eds, *Applied Biocatalysis (2nd Edn)* 437

T

Tzotzos, G.T. and Skryabin, K.G., eds, *Biotechnology in the Developing World and Countries in Economic Transition* 322

W

Wilkinson, D.G., ed., In Situ *Hybridization: A Practical Approach* 40

Wink, M., ed., *Biochemistry of Plant Secondary Metabolism and Functions of Plant Secondary Metabolites and their Exploitation in Biotechnology* 321